PT1921077T - Agente para tratar e/ou prevenir distúrbio do sono - Google Patents

Agente para tratar e/ou prevenir distúrbio do sono

Info

Publication number
PT1921077T
PT1921077T PT67821975T PT06782197T PT1921077T PT 1921077 T PT1921077 T PT 1921077T PT 67821975 T PT67821975 T PT 67821975T PT 06782197 T PT06782197 T PT 06782197T PT 1921077 T PT1921077 T PT 1921077T
Authority
PT
Portugal
Prior art keywords
treating
agent
sleep disorder
preventing sleep
preventing
Prior art date
Application number
PT67821975T
Other languages
English (en)
Inventor
Uesaka Noriaki
Ichikawa Shunji
Nakajima Takao
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of PT1921077T publication Critical patent/PT1921077T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
PT67821975T 2005-08-02 2006-08-02 Agente para tratar e/ou prevenir distúrbio do sono PT1921077T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005223547 2005-08-02

Publications (1)

Publication Number Publication Date
PT1921077T true PT1921077T (pt) 2017-10-26

Family

ID=37708808

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67821975T PT1921077T (pt) 2005-08-02 2006-08-02 Agente para tratar e/ou prevenir distúrbio do sono

Country Status (14)

Country Link
US (1) US7928098B2 (pt)
EP (1) EP1921077B1 (pt)
JP (1) JP5121453B2 (pt)
CA (1) CA2617817C (pt)
CY (1) CY1119488T1 (pt)
DK (1) DK1921077T3 (pt)
ES (1) ES2643340T3 (pt)
HU (1) HUE034666T2 (pt)
LT (1) LT1921077T (pt)
PL (1) PL1921077T3 (pt)
PT (1) PT1921077T (pt)
SI (1) SI1921077T1 (pt)
TW (1) TWI457125B (pt)
WO (1) WO2007015528A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551611C (en) * 2003-12-26 2013-06-25 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
EP1794157B1 (en) 2004-09-22 2014-02-26 H. Lundbeck A/S 2-acylaminothiazole derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
AU2007288245A1 (en) 2006-08-24 2008-02-28 Novartis Ag 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders
WO2008036715A1 (en) 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
CN101595105B (zh) 2006-12-20 2013-01-23 诺瓦提斯公司 作为scd抑制剂的2-取代的5元杂环化合物
CA2731573C (en) * 2008-07-23 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Selective adenosine a2a receptor antagonists useful in the treatment and prevention of migraine
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
PE20150229A1 (es) 2012-05-31 2015-03-02 Phenex Pharmaceuticals Ag Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano rory
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2016087615A1 (en) * 2014-12-04 2016-06-09 Procomcure Biotech Gmbh Novel imidazole-based heterocyclic compounds
LT3226858T (lt) 2014-12-04 2021-06-10 Procomcure Biotech Gmbh Imidazolo pagrindo antimikrobiniai agentai
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
WO2016160938A1 (en) * 2015-04-02 2016-10-06 Abbvie Inc. N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators
GB2555264A (en) * 2016-04-15 2018-04-25 Univ Oxford Innovation Ltd Adenosine receptor modulators for the treatment of circadian rhythm disorders
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
JPH11193281A (ja) * 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンa3受容体拮抗剤およびチアゾール化合物
AU4506399A (en) 1998-06-05 1999-12-30 Novartis Ag Aryl pyridinyl thiazoles
JP3333774B2 (ja) 1999-04-23 2002-10-15 武田薬品工業株式会社 5−ピリジル−1,3−アゾール化合物、その製造法及び用途
ES2275500T3 (es) * 1999-04-23 2007-06-16 Takeda Pharmaceutical Company Limited Compuestos de 5-piridil-1,3-azol, procedimiento para su produccion y uso de los mismos.
JP2002302488A (ja) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd 置換1,3−チアゾール化合物、その製造法および用途
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US6643966B2 (en) * 2001-03-05 2003-11-11 Anthony J. Schmitt Banner sign display stand
WO2002079204A1 (fr) * 2001-03-28 2002-10-10 Kyowa Hakko Kogyo Co., Ltd. Derive 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine
TWI330183B (pt) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
JP2005510508A (ja) 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類
GB0130705D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
CA2551611C (en) 2003-12-26 2013-06-25 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
EP1794157B1 (en) 2004-09-22 2014-02-26 H. Lundbeck A/S 2-acylaminothiazole derivatives
EP1894930A4 (en) * 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE

Also Published As

Publication number Publication date
WO2007015528A1 (ja) 2007-02-08
CA2617817C (en) 2014-05-27
EP1921077A4 (en) 2009-01-28
EP1921077A1 (en) 2008-05-14
CY1119488T1 (el) 2018-03-07
PL1921077T3 (pl) 2018-01-31
TWI457125B (zh) 2014-10-21
HUE034666T2 (hu) 2018-02-28
TW200740434A (en) 2007-11-01
DK1921077T3 (en) 2017-10-23
JP5121453B2 (ja) 2013-01-16
ES2643340T3 (es) 2017-11-22
US7928098B2 (en) 2011-04-19
US20100152162A1 (en) 2010-06-17
SI1921077T1 (sl) 2017-11-30
LT1921077T (lt) 2017-09-25
EP1921077B1 (en) 2017-07-26
JPWO2007015528A1 (ja) 2009-02-19
CA2617817A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
PL1921077T3 (pl) Środek do zapobiegania i/lub leczenia zaburzenia snu
ZA200802415B (en) Method and means of preventing and treating sleep disordered breathing
EP2004630A4 (en) 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES RELATED TO PROTEIN A
IL190745A0 (en) Microangiopathy treatment and prevention
IL243317A0 (en) Exendin for the treatment of diabetes and weight loss
HK1216080A1 (zh) 用於治療或預防草酸鹽相關疾病的組合物和方法
IL186599A0 (en) Methods for treating and preventing fibrosis
PL2520295T3 (pl) Sposób zapobiegania i leczenia zapalenia błon śluzowych
IL185056A0 (en) Compositions and methods for treating or preventing flaviviridae infections
EP1987397A4 (en) APPARATUS AND METHODS OF WRITING
EP1923388A4 (en) BRAIN / NERVE CELL PROTECTION AND THERAPEUTIC FOR SLEEP DISORDERS
IL192568A0 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
ZA200708575B (en) Methods and compositions for treating or preventing cancer
EP2222359A4 (en) DEVICES AND METHOD FOR TREATMENT OF BREATHING IN SLEEP
EP1930385A4 (en) AQUEOUS SURFACE TREATMENT AGENT AND SURFACE-TREATED STRUCTURE
PL1806134T3 (pl) Środek i produkt żywnościowy do zapobiegania/leczenia czynnościowych zaburzeń trawiennych
IL183520A0 (en) Preventive or therapeutic agent for sleep disorder
EP1948184A4 (en) REDUCTION OF CELLULAR CHOLESTERIN MIRRORS AND / OR TREATMENT OR PREVENTION OF PHOSPHOLIPIDOSIS
AU2006276675A8 (en) Sleep disorder treating device and sleep disorder treating method
HK1126123A1 (en) Agent for prevention and treatment of acute renal failure
EP1859826A4 (en) CONTRAST REMOVAL SYSTEM AND METHOD FOR ACTIVATING THE CONTRAST REMOVAL SYSTEM
IL197766A0 (en) Use of oritavancin for the prevention and treatment of anthrax
EP1898921A4 (en) COMPOSITIONS AND METHODS FOR TREATING SLEEP DISORDERS
SG126810A1 (en) Method for preventing or treating respiratory infections in infants
EP1959982A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND / OR TREATING PANCREATITIS